RxDoctor Payments Data

Amanda Gudgell, DO

Pulmonary Disease · Topeka, KSNPI 1770702201

Payments from drug & device makers

$856in general payments, 2019–2025

Across 44 payments — averaging $19.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$210
  • GSK$121
  • Boehringer Ingelheim$95
  • Sanofi$79
  • Grifols USA, LLC$63
  • Regeneron Healthcare Solutions, Inc.$55
  • plus $234 from 10 others

What the payments were for

  • Food & beverage$82797%
  • Education$293%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$856 in reported general payments places this provider in the 30th percentile of 92 pulmonary disease providers in Kansas.

See all pulmonary disease providers in Kansas

Medicare billing

Part B allowed, 2024
$129,284
Medicare patients
648
Services billed
2,195

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter360$271,040
Breo ElliptaFluticasone/Vilanterol123$54,425
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr94$44,644
Breztri AerosphereBudesonide/Glycopyr/Formoterol33$28,335
EliquisApixaban24$14,922
Stiolto RespimatTiotropium Br/Olodaterol Hcl21$11,518
Arnuity ElliptaFluticasone Furoate52$10,267
SymbicortBudesonide/Formoterol Fumarate30$8,394
Fluticasone-SalmeterolFluticasone Propion/Salmeterol68$7,801
Bevespi AerosphereGlycopyrrolate/Formoterol Fum15$7,141
Albuterol Sulfate HfaAlbuterol Sulfate266$6,283
Ventolin HfaAlbuterol Sulfate50$3,293
BreynaBudesonide/Formoterol Fumarate18$2,744
Mycophenolate Mofetil13$1,276
Fluticasone Propionate66$1,001

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta$121$380,376629 claims
AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere$210$43,86978 claims
Boehringer IngelheimStiolto Respimat$95$11,51821 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 92 pulmonary disease providers in Kansas.

Other pulmonary disease in Topeka

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →